Key drivers of cost-effectiveness
{"Image DocumentName": "Key drivers of cost-effectiveness", "Image ImageDescription": "Trial data will allow exploration of mean costs and QALYs per patient for each trial arm to 28 days. Feasibility trial, so the time horizon is short. Model acute upper GI bleeding (AUGIB) patient pathway & associated costs and outcomes beyond 28 days to identify parameters with the potential to be key drivers of cost-effectiveness. Use trial data, and other sources such as audit of AUGIB. The same model will be used to model costs/ effects beyond 28 days to identify key cost drivers as part of the feasibility trial, as will be used to extrapolate costs and effects beyond the end of the trial time horizon in the phase III trial. But, models being used in different ways. Feasibility \u2013 lots of sensitivity analysis as lot of uncertainty about parameter estimates given v short follow up, and also to test the influence and effects of various parameters. Phase III trial \u2013 model used to draw cost-effectiveness conclusions and assess uncertainty around findings. 20 year time horizon. 81.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}